首页> 外文期刊>Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis >Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers.
【24h】

Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers.

机译:非小细胞肺癌中的血管内皮生长因子(VEGF-A)血浆水平:与凝血和血小板活化标志物的关系。

获取原文
获取原文并翻译 | 示例
           

摘要

Platelet activation, commonly found in lung cancer patients, may cause the release of angiogenic factors, such as vascular endothelial growth factor (VEGF-A). The present study was designed to investigate whether plasma VEGF-A levels were associated to different stages of non-small cell lung cancer (NSCLC). Moreover, sP-selectin, prothrombin fragment 1+2 (F1+2), thrombin-antithrombin III complex (TATc) and D-dimer levels were measured to test the hypothesis of an involvement of platelet and coagulation activation in tumor angiogenesis. VEGF-A, sP-selectin, F1+2, TATc and D-dimer levels were elevated in 65 patients with NSCLC, particularly in metastatic patients. sP-selectin (p <0.003) and F1+2 (p <0.005) levels were independently associated to VEGF-A. In addition, patients with positive levels of both sP-selectin and F1+2 had the highest levels of VEGF-A. In conclusion, our findings support the hypothesis that thrombin generation might induce platelet activation and VEGF-A release in NSCLC.
机译:通常在肺癌患者中发现的血小板激活可能会导致血管生成因子(如血管内皮生长因子(VEGF-A))的释放。本研究旨在调查血浆VEGF-A水平是否与非小细胞肺癌(NSCLC)的不同阶段相关。此外,测量了sP-选择素,凝血酶原片段1 + 2(F1 + 2),凝血酶-抗凝血酶III复合物(TATc)和D-二聚体水平,以检验有关血小板和凝血激活参与肿瘤血管生成的假设。 65例NSCLC患者,尤其是转移性患者中,VEGF-A,sP-选择蛋白,F1 + 2,TATc和D-二聚体水平升高。 sP-选择蛋白(p <0.003)和F1 + 2(p <0.005)的水平与VEGF-A独立相关。此外,sP-选择蛋白和F1 + 2阳性的患者的VEGF-A水平最高。总而言之,我们的发现支持以下假设:凝血酶生成可能会诱导NSCLC中的血小板活化和VEGF-A释放。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号